Innovent (IVN) and Lilly Extend Global Oncology & Immunology Collaboration

Innovent Pharmaceuticals (IVN) and Eli Lilly & Company (LLY) announced an expanded collaboration to co-develop and co-commercialize novel oncology and immunology therapies, effective February 15, 2026. The agreement extends Lilly's existing portfolio of investigational agents into Asia-Pacific and expands Innovent's capabilities in the U.S. and Europe. Financial terms were not disclosed, but the companies expect the collaboration to drive revenue growth and expand access to patients globally. The expanded partnership is designed to leverage Lilly's research pipeline and Innovent's commercial expertise to accelerate approvals and market entry.